Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review

Multiple Sclerosis

Volumn 21, Issue 12, 2015, Pages 1485-1495

  Plemel, Jason R ^a   Juzwik, Camille A ^b   Benson, Curtis A ^c   Monks, Michael ^d   Harris, Chelsea ^d   Ploughman, Michelle ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Alpha lipoic acid; alternative therapies; complementary; Ginkgo biloba; oxidative stress; polyphenols; vitamins

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BETA1A INTERFERON; CELL ADHESION MOLECULE; CURCUMIN; EPIGALLOCATECHIN GALLATE; GAMMA INTERFERON; GELATINASE B; GINKGO BILOBA EXTRACT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; LUTEOLIN; NON PRESCRIPTION DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; QUERCETIN; RESVERATROL; RETINOL; THIOCTIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; CATECHIN; STILBENE DERIVATIVE;

ABNORMAL URINE COMPOSITION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CALIFORNIA VERBAL LEARNING TEST; CELL DIFFERENTIATION; CELL INFILTRATION; CELL PROLIFERATION; CELL VIABILITY; COGNITIVE DEFECT; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GASTROINTESTINAL SYMPTOM; HUMAN; MALODOROUS URINE; MEMORY TEST; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; OPTIC NERVE LESION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; STROOP TEST; SYSTEMATIC REVIEW; TH1 CELL; TH17 CELL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL THRESHOLD SERIAL ADDITION TEST; WECHSLER MEMORY SCALE; ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); GINKGO BILOBA; REVIEW; RISK ASSESSMENT; ANALOGS AND DERIVATIVES; ANIMAL;

ANIMALS; ANTIOXIDANTS; CATECHIN; GINKGO BILOBA; HUMANS; MULTIPLE SCLEROSIS; NONPRESCRIPTION DRUGS; QUERCETIN; STILBENES; THIOCTIC ACID;

EID: 84985909391     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515601513     Document Type: Article

References (86)

1. Bjartmar C, Trapp BD,. Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res 2003; 5: 157-164.
2. Coles AJ, Wing MG, Molyneux P, et al.,. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304.
3. Metz I, Lucchinetti CF, Openshaw H, et al.,. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 2007; 130: 1254-1262.
4. Scalfari A, Neuhaus A, Degenhardt A, et al.,. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain 2010; 133: 1914-1929.
5. Trapp BD, Stys PK,. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8: 280-291.
6. Geurts JJ, Stys PK, Minagar A, et al.,. Gray matter pathology in (chronic) MS: Modern views on an early observation. J Neurol Sci 2009; 282: 12-20.
7. Rudick RA, Trapp BD,. Gray-matter injury in multiple sclerosis. N Engl J Med 2009; 361: 1505-1506.
8. Franklin RJ, ffrench-Constant C, Edgar JM, et al.,. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 2012; 8: 624-634.
9. Smith KJ, Kapoor R, Felts PA,. Demyelination: The role of reactive oxygen and nitrogen species. Brain Pathol 1999; 9: 69-92.
10. Haider L, Fischer MT, Frischer JM, et al.,. Oxidative damage in multiple sclerosis lesions. Brain 2011; 134: 1914-1924.
11. Cross AH, Manning PT, Keeling RM, et al.,. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 1998; 88: 45-56.
12. Liu JS, Zhao ML, Brosnan CF, et al.,. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001; 158: 2057-2066.
13. Fischer MT, Sharma R, Lim JL, et al.,. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012; 135: 886-899.
14. Nikic I, Merkler D, Sorbara C, et al.,. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2011; 17: 495-499.
15. Masullo L, Papas MA, Cotugna N, et al.,. Complementary and alternative medicine use and nutrient intake among individuals with multiple sclerosis in the United States. J Commun Health 2015; 40: 153-160.
16. Liberati A, Altman DG, Tetzlaff J, et al.,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol 2009; 62: e1-34.
17. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
18. Vesterinen HM, Egan K, Deister A, et al.,. Systematic survey of the design, statistical analysis, and reporting of studies published in the 2008 volume of the. Journal of Cerebral Blood Flow and Metabolism. J Cereb Blood Flow Metab 2011; 31: 1064-1072.
19. Sena E, van der Worp HB, Howells D, et al.,. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci 2007; 30: 433-439.
20. Liu B, Shen Y, Xiao K, et al.,. Serum uric acid levels in patients with multiple sclerosis: A meta-analysis. Neurol Res 2012; 34: 163-171.
21. Spitsin S, Koprowski H,. Role of uric acid in multiple sclerosis. Curr Top Microbiol 2008; 318: 325-342.
22. Koch M, De Keyser J,. Uric acid in multiple sclerosis. Neurol Res 2006; 28: 316-319.
23. Farinotti M, Vacchi L, Simi S, et al.,. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev 2012; 12: CD004192.
24. Scalbert A, Johnson IT, Saltmarsh M,. Polyphenols: Antioxidants and beyond. Am J Clin Nutr 2005; 81: 215S-217S.
25. Tangney CC, Rasmussen HE,. Polyphenols, inflammation, and cardiovascular disease. Curr Atheroscler Rep 2013; 15: 324.
26. Hendriks JJ, Alblas J, van der Pol SM, et al.,. Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J Exp Med 2004; 200: 1667-1672.
27. Muthian G, Bright JJ,. Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J Clin Immunol 2004; 24: 542-552.
28. Sternberg Z, Chadha K, Lieberman A, et al.,. Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. J Neuroimmunol 2008; 205: 142-147.
29. Verbeek R, van Tol EA, van Noort JM,. Oral flavonoids delay recovery from experimental autoimmune encephalomyelitis in SJL mice. Biochem Pharmacol 2005; 70: 220-228.
30. Sternberg Z, Chadha K, Lieberman A, et al.,. Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: Additive effects of IFN-beta. J Neuroinflammation 2009; 6: 28.
31. Natarajan C, Bright JJ,. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 2002; 168: 6506-6513.
32. Xie L, Li XK, Funeshima-Fuji N, et al.,. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 2009; 9: 575-581.
33. Fonseca-Kelly Z, Nassrallah M, Uribe J, et al.,. Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol 2012; 3: 84.
34. Imler TJ Jr., Petro TM,. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression. Int Immunopharmacol 2009; 9: 134-143.
35. Shindler KS, Ventura E, Dutt M, et al.,. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol 2010; 30: 328-339.
36. Singh NP, Hegde VL, Hofseth LJ, et al.,. Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 2007; 72: 1508-1521.
37. Aktas O, Prozorovski T, Smorodchenko A, et al.,. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 2004; 173: 5794-5800.
38. Herges K, Millward JM, Hentschel N, et al.,. Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation. PLoS One 2011; 6: e25456.
39. Sun Q, Zheng Y, Zhang X, et al.,. Novel immunoregulatory properties of EGCG on reducing inflammation in EAE. Front Biosci (Landmark Ed) 2013; 18: 332-342.
40. Wang J, Ren Z, Xu Y, et al.,. Epigallocatechin-3-gallate ameliorates experimental autoimmune encephalomyelitis by altering balance among CD4+ T-cell subsets. Am J Pathol 2012; 180: 221-234.
41. Barry J, Fritz M, Brender JR, et al.,. Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: The case of the antioxidant curcumin. J Am Chem Soc 2009; 131: 4490-4498.
42. Wang KC, Tsai CP, Lee CL, et al.,. alpha-Lipoic acid enhances endogenous peroxisome-proliferator-activated receptor-gamma to ameliorate experimental autoimmune encephalomyelitis in mice. Clin Sci (Lond) 2013; 125: 329-340.
43. Furst R, Zundorf I,. Plant-derived anti-inflammatory compounds: Hopes and disappointments regarding the translation of preclinical knowledge into clinical progress. Mediators Inflamm 2014; 2014: 146832.
44. Goudarzvand M, Javan M, Mirnajafi-Zadeh J, et al.,. Vitamins E and D3 attenuate demyelination and potentiate remyelination processes of hippocampal formation of rats following local injection of ethidium bromide. Cell Mol Neurobiol 2010; 30: 289-299.
45. Jafarirad S, Siassi F, Harirchian MH, et al.,. The effect of vitamin A supplementation on biochemical parameters in multiple sclerosis patients. Iran Red Crescent Med J 2013; 15: 194-198.
46. Jafarirad S, Siassi F, Harirchian MH, et al.,. The effect of vitamin A supplementation on stimulated T-cell proliferation with myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. J Neurosci Rural Pract 2012; 3: 294-298.
47. Mai J, Sorensen PS, Hansen JC,. High dose antioxidant supplementation to MS patients. Effects on glutathione peroxidase, clinical safety, and absorption of selenium. Biol Trace Elem Res 1990; 24: 109-117.
48. Nordvik I, Myhr KM, Nyland H, et al.,. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 2000; 102: 143-149.
49. Jensen GE, Clausen J,. Glutathione peroxidase activity, associated enzymes and substrates in blood cells from patients with multiple sclerosis-effects of antioxidant supplementation. Acta Pharmacol Toxicol (Copenh) 1986; 59 (Suppl 7): 450-453.
50. Pantzaris MC, Loukaides GN, Ntzani EE, et al.,. A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: A randomised, double-blind, placebo-controlled proof-of-concept clinical trial. BMJ Open 2013; 3: e002170. DOI: 10.1136/bmjopen-2012-002170.
51. Ramsaransing GS, Mellema SA, De Keyser J,. Dietary patterns in clinical subtypes of multiple sclerosis: An exploratory study. Nutr J 2009; 8: 36.
52. Shinto L, Calabrese C, Morris C, et al.,. A randomized pilot study of naturopathic medicine in multiple sclerosis. J Altern Complement Med 2008; 14: 489-496.
53. Spanevello R, Mazzanti CM, Schmatz R, et al.,. Effect of vitamin E on ectonucleotidase activities in synaptosomes and platelets and parameters of oxidative stress in rats experimentally demyelinated. Brain Res Bull 2009; 80: 45-51.
54. Spitsin SV, Scott GS, Mikheeva T, et al.,. Comparison of uric acid and ascorbic acid in protection against EAE. Free Radic Biol Med 2002; 33: 1363-1371.
55. Vladutiu A, Cringulescu N,. Suppression of experimental allergic encephalomyelitis by vitamin A. Experientia 1968; 24: 718-719.
56. Zhang SM, Hernan MA, Olek MJ, et al.,. Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women. Neurology 2001; 57: 75-80.
57. Brigelius-Flohé R, Traber MG,. Vitamin E: Function and metabolism. FASEB J 1999; 13: 1145-1155.
58. Boscoboinik D, Szewczyk A, Azzi A,. Alpha-tocopherol (vitamin E) regulates vascular smooth muscle cell proliferation and protein kinase C activity. Arch Biochem Biophys 1991; 286: 264-269.
59. Chan AC, Wagner M, Kennedy C, et al.,. Vitamin E up-regulates arachidonic acid release and phospholipase A2 in megakaryocytes. Mol Cell Biochem 1998; 189: 153-159.
60. Nebbioso M, Pranno F, Pescosolido N,. Lipoic acid in animal models and clinical use in diabetic retinopathy. Expert Opin Pharmacother 2013; 14: 1829-1838.
61. Rochette L, Ghibu S, Richard C, et al.,. Direct and indirect antioxidant properties of alpha-lipoic acid and therapeutic potential. Mol Nutr Food Res 2013; 57: 114-125.
62. Yadav V, Marracci GH, Munar MY, et al.,. Pharmacokinetic study of lipoic acid in multiple sclerosis: Comparing mice and human pharmacokinetic parameters. Mult Scler 2010; 16: 387-397.
63. Salinthone S, Yadav V, Schillace RV, et al.,. Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling. PLoS One 2010; 5 (9): e13058. DOI: 10.1371/journal.pone.0013058.
64. Khalili M, Azimi A, Izadi V, et al.,. Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: A double-blind, placebo-controlled, randomized clinical trial. Neuroimmunomodulation 2014; 21 (6): 291-6. DOI: 10.1159/000356145.
65. Khalili M, Eghtesadi S, Mirshafiey A, et al.,. Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial. Nutr Neurosci 2014; 17: 16-20.
66. Chaudhary P, Marracci G, Yu X, et al.,. Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis. J Neuroimmunol 2011; 233: 90-96.
67. Chaudhary P, Marracci GH, Bourdette DN,. Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis. J Neuroimmunol 2006; 175: 87-96.
68. Jones RE, Moes N, Zwickey H, et al.,. Treatment of experimental autoimmune encephalomyelitis with alpha lipoic acid and associative conditioning. Brain Behav Immun 2008; 22: 538-543.
69. Marracci GH, Jones RE, McKeon GP, et al.,. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 131: 104-114.
70. Morini M, Roccatagliata L, Dell'Eva R, et al.,. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 148: 146-153.
71. Schreibelt G, Musters RJ, Reijerkerk A, et al.,. Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity. J Immunol 2006; 177: 2630-2637.
72. Yadav V, Marracci G, Lovera J, et al.,. Lipoic acid in multiple sclerosis: A pilot study. Mult Scler 2005; 11: 159-165.
73. van Beek TA,. Chemical analysis of Ginkgo biloba leaves and extracts. J Chromatogr A 2002; 967: 21-55.
74. Johnson SK, Diamond BJ, Rausch S, et al.,. The effect of Ginkgo biloba on functional measures in multiple sclerosis: A pilot randomized controlled trial. Explore (NY) 2006; 2: 19-24.
75. Lovera JF, Kim E, Heriza E, et al.,. Ginkgo biloba does not improve cognitive function in MS: A randomized placebo-controlled trial. Neurology 2012; 79: 1278-1284.
76. Lovera J, Bagert B, Smoot K, et al.,. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: A randomized, placebo-controlled trial. Mult Scler 2007; 13: 376-385.
77. Noroozian M M-RS, Tasviechi AK, Sahraian MA, et al.,. Gingko biloba for improvement of memory and quality of life in multiple sclerosis: An open trial. J Med Plants 2011; 10: 33-42.
78. Diamond BJ, Johnson SK, Kaufman M, et al.,. A randomized controlled pilot trial: The effects of EGb 761 on information processing and executive function in multiple sclerosis. Explore (NY) 2013; 9: 106-107.
79. Hawker K, O'Connor P, Freedman MS, et al.,. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-471.
80. Lassmann H,. Multiple sclerosis: Lessons from molecular neuropathology. Exp Neurol 2013; 262 (Part A): 2-7.
81. Dysken MW, Sano M, Asthana S, et al.,. Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA 2014; 311: 33-44.
82. Schuh C, Wimmer I, Hametner S, et al.,. Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models. Acta Neuropathol 2014; 128: 247-266.
83. Ratnam DV, Ankola DD, Bhardwaj V, et al.,. Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. J Control Release 2006; 113: 189-207.
84. Ude C, Schubert-Zsilavecz M, Wurglics M,. Ginkgo biloba extracts: A review of the pharmacokinetics of the active ingredients. Clin Pharmacokinet 2013; 52: 727-749.
85. Chng HT, New LS, Neo AH, et al.,. Distribution study of orally administered lipoic acid in rat brain tissues. Brain Res 2009; 1251: 80-86.
86. Lin LC, Wang MN, Tseng TY, et al.,. Pharmacokinetics of (-)-epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution. J Agr Food Chem 2007; 55: 1517-1524.